• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To update the 1998 American Academy of Neurology practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various technologies identify previously undetected NVAF? Which therapies reduce ischemic stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review; modified Delphi process recommendation formulation. Major conclusions: In patients with recent cryptogenic stroke, cardiac rhythm monitoring probabl...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., Gronseth, G. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research

Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
Conclusions: Percutaneous PFO closure with the STARFlex device possibly does not provide a benefit in preventing stroke vs medical therapy alone (risk difference [RD] 0.13%, 95% confidence interval [CI] –2.2% to 2.0%). Percutaneous PFO closure with the AMPLATZER PFO Occluder possibly decreases the risk of recurrent stroke (RD –1.68%, 95% CI –3.18% to –0.19%), possibly increases the risk of new-onset atrial fibrillation (AF) (RD 1.64%, 95% CI 0.07%–3.2%), and is highly likely to be associated with a procedural complication risk of 3.4% (95% CI 2.3%–5%). There is insufficient evidence to d...
Source: Neurology - August 21, 2016 Category: Neurology Authors: Messe, S. R., Gronseth, G., Kent, D. M., Kizer, J. R., Homma, S., Rosterman, L., Kasner, S. E. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research

Does Prior Use of Beta Blockers Affect Functional Outcomes Post Ischemic Stroke Endovascular Intervention? (P5.296)
Conclusions:Prior use of beta blockers did not lead to better functional outcomes (MRS ≤2) in acute ischemic stroke patients undergoing EVI. Findings should be further confirmed in larger population.Disclosure: Dr. Albadareen has nothing to disclose. Dr. Gronseth has received personal compensation in an editorial capacity for Neurology. Dr. Gronseth has received research support from the American Academy of Neurology. Dr. Mittal has nothing to disclose. Dr. Sharrock has nothing to disclose. Dr. Keshary has nothing to disclose. Dr. Abraham has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Albadareen, R., Gronseth, G., Mittal, M., Sharrock, M., Keshary, S., Abraham, M. Tags: Stroke Recovery and Rehabilitation Source Type: research

Pattern and risk factors of stroke in the young among stroke patients admitted in medical college hospital, Thiruvananthapuram
Conclusion: In all, 15% of total stroke occurred in young adults <50 years. The proportion of hemorrhagic stroke in young adults is higher than in elderly. Atrial fibrillation is identified as an independent risk factor of stroke in the young. Compared with stroke in elderly alcohol use, smoking, hyperlipidemia, and cardiac diseases, which are known risk factors, are higher in young stroke.
Source: Annals of Indian Academy of Neurology - February 10, 2015 Category: Neurology Authors: Praveen Prasannakumar SubhaSabarinadh Muraleedharan Pillai GeethakumariMohan AthiraZinia Thajudeen Nujum Source Type: research

Wake-up Stroke and Onset-to-door Duration Delays: Potential Future Indications for Reperfusion Therapy.
Conclusion: The one- third proportion of wake-up stroke in this cohort and low prevalence of relative contraindications suggest this is a promising group for emerging thrombolysis indications. With the majority of patients presenting after 8 hours, widening of the therapeutic window with new potential reperfusion treatments would not appreciably increase treatment utilisation. This study reaffirms the urgent need for public education to improve stroke awareness in Singapore. PMID: 24557460 [PubMed - in process]
Source: Annals of the Academy of Medicine, Singapore - January 1, 2014 Category: Journals (General) Authors: Tan MSh, Ang ES, Ho SS, Ng SC, Talabucon L, Woon FP, De Silva DA Tags: Ann Acad Med Singapore Source Type: research

Clinical features, risk factors, and short-term outcome of ischemic stroke, in patients with atrial fibrillation: Data from a population-based study
Conclusions: Ten percent of stroke patients had AF. They were older, had multiple risk factors and worse outcome. There was no gender difference in this large cohort.
Source: Annals of Indian Academy of Neurology - August 10, 2017 Category: Neurology Authors: G William Akanksha Kaur Paramdeep Singh Gagandeep Bansal Rajinder S Paul Birinder Singla Monika Singh Shavinder J Samuel Clarence J Verma Shweta Meenakshi Sharma D Pandian Jeyaraj Source Type: research

Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
CONCLUSION: PFO closure can be considered for the prevention of recurrent cryptogenic stroke in patients aged ≤60 years after a thorough evaluation and discussion about benefits and potential risks (including but not limited to atrial fibrillation) of the procedure. Accumulating evidence supports prognostic, quality of life, and economic benefit from percutaneous PFO closure with newer generation closure devices in the right subset of patients. PMID: 33460329 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - January 20, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research

Infarct volumes of patients with acute ischemic stroke receiving direct oral anticoagulants due to non-valvular atrial fibrillation
Conclusion: We observe, while using DOACs, the infarct volumes of patients who experience stroke are smaller than those with NDAF and using ASA, as well as mRS scores at discharge are low and length of hospital stay is short.
Source: Annals of Indian Academy of Neurology - February 16, 2021 Category: Neurology Authors: Nese G Yavasoglu Yasemin Eren Idil G Tatar Irfan Yalcinkaya Source Type: research

Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation
ConclusionsDOACs are at least as effective as warfarin for stroke prevention in elderly patients with NVAF. Compared with warfarin, DOACs were associated with reduced risk of intracranial hemorrhage, while some DOACs demonstrated an increase in other bleeding events (e.g., gastrointestinal). The faster onset and offset of action and fewer food and drug interactions of DOACs may be an advantage over warfarin for some patients. Implications for practiceDOACs are an alternative to warfarin with overall equivalent safety and efficacy in elderly patients with NVAF, and may be preferable for some. Stroke risk must always be bala...
Source: Journal of the American Academy of Nurse Practitioners - August 14, 2017 Category: Nursing Authors: Lynn B. Oertel, Annemarie E. Fogerty Tags: REVIEW ‐ SPONSORED Source Type: research

Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update
Atrial fibrillation is a common, potentially preventable cause of disabling stroke in the elderly, particularly in elderly women, resulting from embolism of stasis-precipitated thrombi formed in the left atrial appendage. In 1989, the first randomized clinical trial of anticoagulant therapy in atrial fibrillation showed that warfarin produced a large reduction in ischemic stroke.1 In the ensuing 25 years, more than 40 additional randomized trials have permitted stroke prophylaxis to be importantly refined. It has been a period of remarkable progress in stroke prevention. Here, we discuss selected aspects of the American Ac...
Source: Nature Clinical Practice - April 14, 2014 Category: Neurology Authors: Hart, R. G., Eikelboom, J. W. Tags: Guideline Perspective Source Type: research

Epidemiology of young stroke in the ludhiana population-based stroke registry
Conclusion: Hypertension, diabetes mellitus, drug addiction, and tobacco intake were significantly associated with young stroke. Outcome was also better in younger people.
Source: Annals of Indian Academy of Neurology - February 22, 2022 Category: Neurology Authors: Monika Singla Gagandeep Singh Paramdeep Kaur Jeyaraj D Pandian Source Type: research

Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin. The development of apixaban reflects a strategy to optimize the clinical pharmacology profile, dosing posology, trial designs, and statistical analyses across multiple indications, and to seek alignment with global health authorities. The primary objective of dose selection was to maintain balance between efficacy and bleeding risk. Twice‐daily dosing of apixaban, rather than once daily, was chosen to lower peak concentrations and re...
Source: Annals of the New York Academy of Sciences - November 5, 2014 Category: Science Authors: Michael S. Hanna, Puneet Mohan, Robert Knabb, Elora Gupta, Charles Frost, John H. Lawrence Tags: Original Article Source Type: research

Advances in stroke prevention
Stroke remains to be a leading cause of disability. However, optimal strategies can prevent up to 80% of strokes. A large body of evidence supports many strategies for primary and secondary prevention of stroke. The purpose of this paper is to highlight recent major advances for management of modifiable medical and behavioral risk factors of stroke. Specific studies are highlighted, including those related to atrial fibrillation (AF), hypertension, revascularization, hyperlipidemia, antiplatelets, smoking, diet, and physical activity. Effective strategies include the use of novel oral anticoagulants for AF, antiplatelet th...
Source: Annals of the New York Academy of Sciences - March 16, 2015 Category: Science Authors: Ayesha Z. Sherzai, Mitchell S.V. Elkind Tags: Original Article Source Type: research

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.
Abstract The last ten years have seen rapid strides in the evolution of nonvitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). For the preparation of this consensus, a comprehensive literature search was performed and data on available trials, subpopulation analyses, and case reports were analyzed. This Indian consensus document intends to provide guidance on selecting the right NOAC for the right patients by formulating expert opinions based on the available trials and Asian/Indian subpopulation analyses of these trials. A section has been dedicated to the curren...
Source: Indian Heart J - December 1, 2015 Category: Cardiology Authors: Dalal J, Bhave A, Oomman A, Vora A, Saxena A, Kahali D, Poncha F, Gambhir DS, Chaudhuri JR, Sinha N, Ray S, Iyengar SS, Banerjee S, Kaul U, SPAF Academy India experts Tags: Indian Heart J Source Type: research

Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update
We thank Drs. Hart and Eikelboom1 for their insightful commentary in Neurology® Clinical Practice regarding the American Academy of Neurology (AAN) evidence-based guideline update on atrial fibrillation (AF).2 Both authors have extensively researched stroke prevention in patients with AF3 and we respect their views. The Commentary states, "atrial fibrillation patients with prior ischemic stroke or TIA benefit the most from anticoagulation and should receive anticoagulation, if it can be given safely." We could not agree more. The AAN guideline development process yields a Level B recommendation when clinicians "should"...
Source: Nature Clinical Practice - June 9, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R. Tags: The Nerve! Readers Speak Source Type: research

Pages: 1  2  3